September 6, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO) (OTCQB: ICOTF), today announced additional positive pharmacokinetic data from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate. Previously the Company reported that Oral Amp B achieved a median Cmax of 28 ng/mL and AUC0-inf of 1030 hr*ng/mL at the lowest dose of Oral Amphotericin B of 100 mg, demonstrating superiority of area under the concentration time curve from time zero to infinity, when compared to published 200 mg, 400 mg and 800 mg oral cochleate formulation data by the closest competitor. Today iCo reported a median AUC0-inf of 2029 hr*ng/mL at the 400 mg dose of Oral Amphotericin B, representing an approximate doubling of the critical AUC0-inf measure at an increased dose. The Company intends to study both the 100 mg and 400 mg dose in the next clinical study. In its Phase 1 study 100 mg, 200 mg, 400 mg and 800 mg doses were studied.
Stated Dr. Peter Hnik “The prolonged plasma half-life and increased AUC as a function of dose suggests that the oral Amphotericin B formulation has a long circulation time which may result in the ability of the formulation to increase Amphotericin B tissue concentrations within infected tissues without the associated GI, liver and kidney toxicity”.
iCo Therapeutics also announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.
iCo Therapeutics Management will provide an overview of the Company’s business during the live presentation.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
Event: 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC
Date: September 4-6, 2018
Time: 3:50 PM – 4:15 PM (Eastern Time)
Location: Louis XVI A (Second Floor); St. Regis New York Hotel in New York City
Additionally the presentation, including graphical 100 mg and 400 mg data, will be posted on the Company’s website: www.icotherapeutics.com immediately after the presentation.
About iCo Therapeutics
iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company’s core focus areas and if so the Company will seek to capture further value via partnerships, such as its partnership with Immune Pharmaceuticals (NASDAQ: IMNP), which is in several Phase 2 studies involving iCo-008. iCo shares trade on the TSX Venture Exchange under the symbol “ICO” and on the OTCQB under the symbol “ICOTF”.
For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor itsRegulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this press release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking statements” within the meaning ofapplicable securities laws. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,”“seek,” “believe,” “project,” “estimate,” “suggest”, “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” and similarreferences to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may causeactual results, performance or achievements to be materially different from those implied by such statements, and thereforethese statements should not be read as guarantees of future performance or results. All forward-looking statements are basedon iCo’s current beliefs as well as assumptions made by and information currently available to iCo and relate to, among otherthings, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance andfuture commitments, including statements relating to the potential implications of data from the Phase 1 study for iCo-019, andintentions regarding future clinical trials. Readers are cautioned not to place undue reliance on these forward-lookingstatements, which are based only on information currently available to iCo and speak only as of the date of this press release.Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on itswebsite, actual events may differ materially from current expectations. In evaluating forward-looking statements, readersshould consider the risk factors set out herein and in the Company’s Annual Information Form dated July 23, 2018, a copy ofwhich is available under ICo’s profile on SEDAR at www.sedar.com and as otherwise disclosed in the Company’s filings under itsprofile on SEDAR from time to time. All forward-looking statements are made as of the date of this press release, and iCodisclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of newinformation, future events or otherwise, except as required by law.
Andrew Rae, CEO 778-772-7775 firstname.lastname@example.org